SLR OF ECONOMIC EVALUATION FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN UK

被引：0
|
作者：
Mehta, J. [1 ]
Harrison, O. [2 ]
Barwood, C. [3 ]
Ubi, S. [3 ]
Bertranou, E. [2 ]
Bouhlabel, F. [4 ]
Low, E. [5 ]
Shah, A. [6 ]
Korde, R. [4 ]
Shah, J. [4 ]
Gaugris, S. [3 ]
机构：
[1] Karyopharm Therapeut, Lexington, MA USA
[2] FIECON, London, Lon, England
[3] FIECON Ltd, St Albans, Hrt, England
[4] Karyopharm Therapeut, Newton, MA USA
[5] Eric Low Consulting, East Lothian, Scotland
[6] Karyopharm Therapeut, Boston, MA USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN165
引用
收藏
页码：S51 / S52
页数：2
相关论文
共 50 条
  • [41] An SLR of Clinical and Real-World Evidence in Relapsed/Refractory Multiple Myeloma (RRMM) Studies to Inform Clinical Decision-Making in the US
    Forsythe, Anna
    Tomaras, Dimitrios
    Parikh, Kejal
    Copher, Ronda
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E269 - E270
  • [42] Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Yi, Lidan
    Liu, Qiao
    Tan, Chongqing
    Wan, Xiaomin
    Luo, Xia
    Li, Yinbo
    Li, Haiying
    Zeng, Xiaohui
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2024, 17 : 2829 - 2837
  • [43] Treatment Options for Relapsed and Refractory Multiple Myeloma
    Lonial, Sagar
    Mitsiades, Constantine S.
    Richardson, Paul G.
    CLINICAL CANCER RESEARCH, 2011, 17 (06) : 1264 - 1277
  • [44] Lenalidomide for the treatment of relapsed or refractory multiple myeloma
    Weber, D. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 22 - 24
  • [45] Elotuzumab in the treatment of relapsed and refractory multiple myeloma
    Grosicki, Sebastian
    Bednarczyk, Martyna
    Barchnicka, Agnieszka
    Grosicka, Olga
    FUTURE ONCOLOGY, 2021, 17 (13) : 1581 - 1591
  • [46] Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
    Bumma, Naresh
    Richter, Joshua
    Jagannath, Sundar
    Lee, Hans C.
    Hoffman, James E.
    Suvannasankha, Attaya
    Zonder, Jeffrey A.
    Shah, Mansi R.
    Lentzsch, Suzanne
    Baz, Rachid
    Maly, Joseph J.
    Namburi, Swathi
    Pianko, Matthew J.
    Ye, Jing Christine
    Wu, Ka Lung
    Silbermann, Rebecca
    Min, Chang-Ki
    Vekemans, Marie-Christiane
    Munder, Markus
    Byun, Ja Min
    Martinez-Lopez, Joaquin
    Cassady, Kaniel
    Deveaux, Michelle
    Chokshi, Dhruti
    Boyapati, Anita
    Hazra, Anasuya
    Yancopoulos, George D.
    Sirulnik, L. Andres
    Lorenc, Karen Rodriguez
    Kroog, Glenn S.
    Houvras, Yariv
    Dhodapkar, Madhav V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (22)
  • [47] CONSTRUCTION OF EXTERNAL-CONTROL ARMS (ECA) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
    Perkins, A.
    O'Reilly, J.
    Tunaru, F.
    Wallis, J.
    Carpenter, L.
    VALUE IN HEALTH, 2023, 26 (12) : S413 - S413
  • [48] Predictive Biomarkers of Response to Venetoclax in Combination with Cobimetinib in Relapsed/Refractory Multiple Myeloma (RRMM)
    Raval, Aparna
    Hamidi, Habib
    Hwang, Olivia
    Green, Cherie
    Maia, Catarina
    Lasa, Marta
    Onishi, Maika
    Rodriguez-Otero, Paula
    San-Miguel, Jesus F.
    Gallo, Jorge D.
    Paiva, Bruno
    Schjesvold, Fredrik
    BLOOD, 2020, 136
  • [49] Pomalidomide for the treatment of relapsed and refractory multiple myeloma
    Guidetti, Anna
    Prada, Claudia Paba
    Laubach, Jacob P.
    Varga, Cindy
    Maglio, Michelle E.
    McKenney, Mary
    Doss, Deborah
    Schlossman, Robert L.
    Mitsiades, Constantine
    Hideshima, Teru
    Gorgun, Gullu T.
    Ghobrial, Irene M.
    Raje, Noopur
    Munshi, Nikhil
    Anderson, Kenneth C.
    Richardson, Paul G.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (10): : 1089 - 1108
  • [50] Thalidomide for the treatment of relapsed and refractory multiple myeloma
    Cool, RM
    Herrington, JD
    PHARMACOTHERAPY, 2002, 22 (08): : 1019 - 1028
12345